Novartis seeks broader ‘incremental’ IP in India with Glivec case
This article was originally published in Scrip
Executive Summary
As Novartis awaits the Supreme Court's verdict in the much publicized Glivec (imatinib mesylate) case in India, the Swiss multinational has stressed that it is seeking a predictable interpretation of the controversial Section 3(d) provision of India's patent law, which it believes should broadened to give due weight to improved safety, among other factors, and not just improved efficacy.